Browse > Article
http://dx.doi.org/10.3340/jkns.2017.0259

Efficacy of Gamma Knife Radiosurgery for Recurrent High-Grade Gliomas with Limited Tumor Volume  

Cheon, Young-Jun (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine)
Jung, Tae-Young (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine)
Jung, Shin (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine)
Kim, In-Young (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine)
Moon, Kyung-Sub (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine)
Lim, Sa-Hoe (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine)
Publication Information
Journal of Korean Neurosurgical Society / v.61, no.4, 2018 , pp. 516-524 More about this Journal
Abstract
Objective : This study aims to determine whether gamma knife radiosurgery (GKR) improves survival in patients with recurrent high-grade gliomas. Methods : Twenty nine patients with recurrent high-grade glioma underwent 38 GKR. The male-to-female ratio was 10 : 19, and the median age was 53.8 years (range, 20-75). GKR was performed in 11 cases of recurrent anaplastic oligodendrogliomas, five anaplastic astrocytomas, and 22 glioblastomas. The median prescription dose was 16 Gy (range, 10-24), and the median target volume was 7.0 mL (range, 1.1-15.7). Of the 29 patients, 13 (44.8%) received concurrent chemotherapy. We retrospectively analyzed the progression-free survival (PFS) and overall survival (OS) after GKR depending on the Eastern Cooperative Oncology Group (ECOG) performance status (PS), pathology, concurrent chemotherapy, radiation dose, and target tumor volume. Results : Starting from when the patients underwent GKR, the median PFS and OS were 5.0 months (range, 1.1-28.1) and 13.0 months (range, 1.1-75.1), respectively. On univariate analysis, the median PFS was significantly long in patients with anaplastic oligodendroglioma, ECOG PS 1, and target tumor volume less than 10 mL (p<0.05). Meanwhile, on multivariate analysis, patients with ECOG PS 1 and target tumor volume less than 10 mL showed improved PFS (p=0.043 and p=0.007, respectively). The median OS was significantly increased in patients with ECOG PS 1 and tumor volume less than 10 mL on univariate and multivariate analyses (p<0.05). Conclusion : GKR could be an additional treatment option in recurrent high-grade glioma, particularly in patients with good PS and limited tumor volume.
Keywords
Recurrence; Glioma; Gamma knife radiosurgery; Tumor volume;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sarkar A, Pollock BE, Brown PD, Gorman DA : Evaluation of gamma knife radiosurgery in the treatment of oligodendrogliomas and mixed oligoden- droastrocytomas. J Neurosurg 97(5 Suppl) : 653-656, 2002
2 Sheehan JP, Lee CC : Stereotactic radiosurgery for recurrent high-grade gliomas. World Neurosurg 82 : e593-e595, 2014   DOI
3 Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A : Clinical management of grade III oligodendroglioma. Cancer Manag Res 7 : 213-223, 2015
4 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005   DOI
5 Bokstein F, Blumenthal DT, Corn BW, Gez E, Matceyevsky D, Shtraus N, et al. : Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. J Neurooncol 126 : 551-557, 2016   DOI
6 Combs SE, Debus J, Schulz-Ertner D : Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 7 : 167, 2007   DOI
7 Conti A, Pontoriero A, Arpa D, Siragusa C, Tomasello C, Romanelli P, et al. : Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. Acta Neurochir (Wien) 154 : 203- 209, 2012   DOI
8 Dodoo E, Huffmann B, Peredo I, Grinaker H, Sinclair G, Machinis T, et al. : Increased survival using delayed gamma knife radiosurgery for recurrent high-grade glioma: a feasibility study. World Neurosurg 82 : e623-e632, 2014   DOI
9 Dong Y, Fu C, Guan H, Zhang T, Zhang Z, Zhou T, et al. : Re-irradiation alternatives for recurrent high-grade glioma. Oncol Lett 12 : 2261-2270, 2016   DOI
10 Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G : Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 81 : 287-294, 2007   DOI
11 Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, et al. : Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103 : 683-691, 2011   DOI
12 Fogh S, Glass C, Andrews DW, Werner-Wasik M : Multiple courses of stereotactic re-irradiation in recurrent oligodendroglioma: a case report. J Med Case Rep 5 : 183, 2011   DOI
13 Kano H, Niranjan A, Khan A, Flickinger JC, Kondziolka D, Lieberman F, et al. : Does radiosurgery have a role in the management of oligodendrogliomas? J Neurosurg 110 : 564-571, 2009   DOI
14 Kim HR, Kim KH, Kong DS, Seol HJ, Nam DH, Lim DH, et al. : Outcome of salvage treatment for recurrent glioblastoma. J Clin Neurosci 22 : 468-473, 2015   DOI
15 Kong DS, Lee JI, Park K, Kim JH, Lim DH, Nam DH : Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 112 : 2046-2051, 2008   DOI
16 Larson DA, Prados M, Lamborn KR, Smith V, Sneed PK, Chang S, et al. : Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 54 : 1397-1404, 2002   DOI
17 Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, et al. : Therapeutic options for recurrent malignant glioma. Radiother Oncol 98 : 1-14, 2011   DOI
18 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. : Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 : 649-655, 1982   DOI
19 Reifenberger GKJBP, Louis DN, Collins VP : Astrocytic and oligodendroglioma in Kleihues P in Cavenee WK (ed) : World health organization classification of tumours, Pathology and genetics of tumours of the nervous system. IARC Press : Lyon, 2000, pp56-67